Eugene Ryfinski, MD
Internal Medicine · Trenton, NJNPI 1073581625
Payments from drug & device makers
Across 216 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$742
- AstraZeneca$289
- Sanofi-aventis U.S. LLC$267
- AbbVie$214
- Lilly USA, LLC$184
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$182
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,237100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $742 |
| AstraZeneca | 19 | $289 |
| Sanofi-aventis U.S. LLC | 18 | $267 |
| AbbVie(2 entities) | 13 | $214 |
| Lilly USA, LLC | 12 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $182 |
| Abbott | 9 | $167 |
| GSK | 10 | $149 |
| Pfizer | 9 | $133 |
| Exact Sciences | 7 | $132 |
| Johnson & Johnson | 9 | $129 |
| Boehringer Ingelheim | 7 | $106 |
| Merck | 6 | $85 |
| Biohaven Pharmaceuticals, Inc. | 4 | $74 |
| Dexcom, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Boston Scientific | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Bayer | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$3,237 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $59,019 |
| TrulicityDulaglutide | 15 | $35,911 |
| OzempicSemaglutide | 14 | $26,894 |
| JanuviaSitagliptin Phosphate | 20 | $24,874 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 44 | $12,860 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 54 | $10,639 |
| FarxigaDapagliflozin Propanediol | 15 | $10,526 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 28 | $8,024 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,720 |
| Mesalamine | 12 | $6,083 |
| Famotidine | 30 | $5,060 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $2,921 |
| SingulairMontelukast Sodium | 11 | $2,804 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $2,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $133 | $71,879116 claims |
| Lilly USA, LLCTrulicity | $184 | $35,91115 claims |
| Novo NordiskOzempic | $742 | $26,89414 claims |
| MerckJanuvia | $85 | $24,87420 claims |
| GSKShingrix, Trelegy Ellipta, Arexvy | $149 | $21,73077 claims |
| AstraZenecaFarxiga | $289 | $10,52615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Trenton
- Jane RohlfTrenton$2.7M
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.